President Donald Trump has once again raised the hopes of Americans by saying that a fax could be produced ahead of the Nov. 3 U.S. presidential election. Although it is a more optimistic timeline than the one given by its top infectious disease expert Dr Anthony Fauci, a vaccine appears to be the only way to eliminate the infection.
Also, millions are pinning their hopes on a handful of drugmakers, who are in the final stages of their vaccine test. In addition, governments are pumping over half a million dollars to secure the first doses of faxes.
Vaccine piles up again
On August 7, Trump said the fax “would be ready by the end of the year. Could be much sooner.” Trump also said there are several facsimiles studying and he is confident that the United States will “do well on facsimiles and therapeutics.”
This is not the first time Trump has made such remarks. Although many experts believe that a vaccine for COVID-19 may take years, many biotech companies and drugmakers are hoping to develop a vaccine by the end of this year or early 2021. Moreover, a large number of companies are already in the finals phase entered their coronavirus vaccine tests, while a few will introduce the last leg shortly.
Vaccination race heats up
Of course, with drug makers and biotech companies making remarkable progress in developing a vaccine in recent months, optimism remains high. Last month, Moderna, Inc. launched MRNA and Pfizer, Inc. PFE two 30,000 test subjects with COVID-19 vaccines who could clear the way for regulatory approval and widespread use by the end of this year, the companies said.
The trials, both announced on the same day, are the first studies in the late stages supported by the Trump administration’s efforts to increase the development of a coronavirus vaccine. Also, the administration is shelling out billions of dollars to secure the first doses of a successful vaccine.
Pharma giants Sanofi SNY and GlaxoSmithKline plc GSK last month said they would receive up to $ 2.1 billion from the U.S. government for the development of a COVID-19 vaccine. Sanofi and GlaxoSmithKline will begin clinical trials of their vaccine candidate in September and the Phase 3 study will be at the end of the year.
On August 3, Eli Lilly and Company LLY announced that they would begin a late-stage trial to study whether any of their experimental COVID-19 antibody treatments could prevent the spread of the virus among residents and staff in the United States.
Shares in Focus
Pfizer shares have advanced 14.9% in the past month. The Zacks’ consensus estimate for current year’s revenue has improved 1.4% over the past 60 days. Pfizer has a Zacks Rank # 3 (Hold).
The expected rate of business expectation for the current year is 3%. The Zacks consensus estimate for revenue for the year has improved 6.7% over the past 60 days. Shares of the company have gained 6.7% so far this year. Gilead has a Zacks Rank # 3.
Amgen’s expected profit growth for the current year is 5.5%. The Zacks consensus estimate for current year income has improved 0.8% over the past 60 days.
The partners will use Medigen’s stable prefix form of the SARS-CoV2 recombinant spike protein in combination with Dynavax’s advanced adjuvant CpG 1018. Dynavax’s shares have increased 83.1% over the past three months. Dynavax has a Zacks Rank # 3.
The hottest tech mega-trend of all
Last year, it generated $ 24 billion in global revenue. By 2020, it is predicted to extinguish the roof to $ 77.6 billion. Well-known investor Mark Cuban says it will produce “the world’s first trillionaires”, but that should still leave a lot of money for regular investors who make the good trade early.
Related
